scholarly journals Vitamin C Symposium 2019—“Vitamin C for Cancer and Infection: From Bench to Bedside”

Proceedings ◽  
2019 ◽  
Vol 5 (1) ◽  
pp. 3
Author(s):  
Anitra Carr
Keyword(s):  
Clinical Trials ◽  
Vitamin C ◽  
Clinical Outcomes ◽  
Respiratory Illness ◽  
Severe Respiratory Illness

The Vitamin C for Cancer and Infection symposium was organised in response to recent international clinical trials that have highlighted the potential for vitamin C administration to improve clinical outcomes for patients with severe respiratory illness, sepsis and some cancers [...]

scholarly journals ZINC SUPPLEMENTATION FOR RESPIRATORY ILLNESS AND ACUTE GASTROENTERITIS AS COMPLEMENT TREATMENT FOR COVID-19

2020 ◽  
Vol 4 (6) ◽  
Author(s):  
Chandrika Murugaiah
Keyword(s):  
Clinical Trials ◽  
Acute Gastroenteritis ◽  
Potential Role ◽  
Zinc Supplementation ◽  
Respiratory Illness ◽  
Atypical Pneumonia ◽  
The Novel ◽  
Duration Of Hospitalization ◽  
Novel Coronavirus ◽  
Severe Respiratory Illness

An outbreak of atypical pneumonia by the novel coronavirus disease 2019 (COVID-19), has been reported in Wuhan, China since December, 2019. It is a severe respiratory illness with many other symptoms such as gastroenteritis. Clinical trials has proved that  Zn is a promising supplement that can ease of cough, fever and vomiting, dysentery, respiratory illness, diarrhea duration and recovery, duration of hospitalization and morbidity. This article suggests a potential role, which should be considered in the clinical management, and safeness for Zn supplementation for respiratory illness and acute gastroenteritis as compliment treatment for covid-19.

scholarly journals Vitamin C in the Treatment of COVID-19

Nutrients ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 1172
Author(s):  
Gregorio Paolo Milani ◽  
Marina Macchi ◽  
Anat Guz-Mark
Keyword(s):  
Clinical Trials ◽  
Vitamin C ◽  
Respiratory Infections ◽  
Medical Condition ◽  
Case Reports ◽  
Case Series ◽  
Theoretical Background ◽  
Current Evidence ◽  
Vitamin C Supplementation ◽  
Essential Nutrient

Vitamin C is an essential nutrient that serves as antioxidant and plays a major role as co-factor and modulator of various pathways of the immune system. Its therapeutic effect during infections has been a matter of debate, with conflicting results in studies of respiratory infections and in critically ill patients. This comprehensive review aimed to summarize the current evidence regarding the use of vitamin C in the prevention or treatment of patients with SARS-CoV2 infection, based on available publications between January 2020 and February 2021. Overall, 21 publications were included in this review, consisting of case-reports and case-series, observational studies, and some clinical trials. In many of the publications, data were incomplete, and in most clinical trials the results are still pending. No studies regarding prevention of COVID-19 with vitamin C supplementation were found. Although some clinical observations reported improved medical condition of patients with COVID-19 treated with vitamin C, available data from controlled studies are scarce and inconclusive. Based on the theoretical background presented in this article, and some preliminary encouraging studies, the role of vitamin C in the treatment of patients with SARS-CoV-2 infection should be further investigated.

scholarly journals Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate

2021 ◽  
Vol 14 ◽  
pp. 175628642097591
Author(s):  
Thomas F. Scott ◽  
Ray Su ◽  
Kuangnan Xiong ◽  
Arman Altincatal ◽  
Carmen Castrillo-Viguera ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Propensity Score ◽  
Clinical Outcomes ◽  
Glatiramer Acetate ◽  
Therapeutic Efficacy ◽  
Individual Patient Data ◽  
Patient Data ◽  
Phase Iii ◽  
Lower Probability ◽  
Phase Iii Clinical Trials

Background: Peginterferon beta-1a and glatiramer acetate (GA) are approved first-line therapies for the treatment of relapsing forms of multiple sclerosis, but their therapeutic efficacy has not been compared directly. Methods: Clinical outcomes at 2 years, including no evidence of disease activity (NEDA), for patients receiving peginterferon beta-1a 125 mcg every 2 weeks (Q2W) or GA 20 mg/ml once daily (QD) were compared by propensity score matching analysis using individual patient data from ADVANCE and CONFIRM phase III clinical trials. In addition, clinical outcomes at 1–3 years for patients receiving peginterferon beta-1a Q2W or GA 40 mg/ml three times a week (TIW) were evaluated using a matching-adjusted comparison analysis of individual patient data from ADVANCE and the ADVANCE extension study, ATTAIN, and aggregate patient data from the phase III GALA and the GALA extension studies. Results: Propensity-score-matched peginterferon beta-1a patients ( n = 336) had a significantly lower annualized relapse rate [ARR (0.204 versus 0.282); rate ratio = 0.724; p = 0.045], a significantly lower probability of 12-week confirmed disability worsening (10.0% versus 14.6%; hazard ratio = 0.625; p = 0.048), and a significantly higher rate of NEDA (20.3% versus 11.5%; p = 0.047) compared with GA 20 mg/ml QD patients after 2 years of treatment. Matching-adjusted peginterferon beta-1a patients (effective n = 276) demonstrated a similar ARR at 1 year (0.278 versus 0.318; p = 0.375) and significantly lower ARR at 2 years (0.0901 versus 0.203; p = 0.032) and 3 years (0.109 versus 0.209; p = 0.047) compared with GA 40 mg/ml TIW patients ( n = 834). Conclusion: Results from separate matching comparisons of phase III clinical trials and extension studies suggest that peginterferon beta-1a 125 mcg Q2W may provide better clinical outcomes than GA (20 mg/ml QD or 40 mg/ml TIW).

scholarly journals To Swab or Not to Swab? The Lesson Learned in Italy in the Early Stage of the COVID-19 Pandemic

2021 ◽  
Vol 11 (9) ◽  
pp. 4042
Author(s):  
Paola Berchialla ◽  
Maria Teresa Giraudo ◽  
Carmen Fava ◽  
Andrea Ricotti ◽  
Giuseppe Saglio ◽  
...  
Keyword(s):  
Early Phase ◽  
Early Stage ◽  
Respiratory Illness ◽  
Explanatory Variables ◽  
Daily Number ◽  
Testing Strategies ◽  
Serious Infections ◽  
The Impact ◽  
Epidemiological Link ◽  
Severe Respiratory Illness

Testing for the SARS-CoV-2 infection is critical for tracking the spread of the virus and controlling the transmission dynamics. In the early phase of the pandemic in Italy, the decentralized healthcare system allowed regions to adopt different testing strategies. The objective of this paper is to assess the impact of the extensive testing of symptomatic individuals and their contacts on the number of hospitalizations against a more stringent testing strategy limited to suspected cases with severe respiratory illness and an epidemiological link to a COVID-19 case. A Poisson regression modelling approach was adopted. In the first model developed, the cumulative daily number of positive cases and a temporal trend were considered as explanatory variables. In the second, the cumulative daily number of swabs was further added. The explanatory variable, given by the number of swabs over time, explained most of the observed differences in the number of hospitalizations between the two strategies. The percentage of the expected error dropped from 70% of the first, simpler model to 15%. Increasing testing to detect and isolate infected individuals in the early phase of an outbreak improves the capability to reduce the spread of serious infections, lessening the burden of hospitals.

scholarly journals VITAMIN C AND UPPER RESPIRATORY ILLNESS IN NAVAHO CHILDREN: PRELIMINARY OBSERVATIONS (1974)

1975 ◽  
Vol 258 (1 Second Confer) ◽  
pp. 513-522 ◽  
Author(s):  
John L. Coulehan ◽  
Louis Kapner ◽  
Susan Eberhard ◽  
Floyd H. Taylor ◽  
Kenneth D. Rogers
Keyword(s):  
Vitamin C ◽  
Respiratory Illness ◽  
Upper Respiratory

scholarly journals Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials

2012 ◽  
Vol 303 (8) ◽  
pp. L634-L639 ◽  
Author(s):  
Ashish Agrawal ◽  
Hanjing Zhuo ◽  
Sandra Brady ◽  
Joseph Levitt ◽  
Jay Steingrub ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Clinical Outcomes ◽  
Predictive Value ◽  
Secondary Analysis ◽  
Activated Protein C ◽  
Oxygenation Index ◽  
Severity Of Illness ◽  
Plasminogen Activator Inhibitor ◽  
High Plasma ◽  
Plasminogen Activator Inhibitor 1

Plasma and bronchoalveolar lavage (BAL) biomarkers related to the pathogenesis of acute lung injury (ALI) have previously been associated with poorer clinical outcomes and increased disease severity among patients with ALI. Whether these biomarkers have predictive value in a less severely ill population that excludes septic patients with high APACHE II scores is currently unknown. We tested the association of plasma and BAL biomarkers with physiological markers of ALI severity or clinically relevant outcomes in a secondary analysis of a clinical trial of activated protein C for the treatment of ALI. Plasma plasminogen activator inhibitor-1 (PAI-1) and mini-BAL protein were both significantly associated with increased oxygenation index ( P = 0.02 and 0.01, respectively), whereas there was a trend toward an association between IL-6 and oxygenation index ( P = 0.057). High plasma IL-6, thrombomodulin, and mini-BAL protein were all significantly associated with fewer ventilator-free days (VFDs) ( P = 0.01, 0.01, and 0.05, respectively); no markers were associated with mortality, but we hypothesized that this was due to the small size of our cohort and the low death rate. To confirm these associations in a larger sample, we identified a restricted cohort of patients from the ARDS Network ALVEOLI study with similar baseline characteristics. We retested the associations of the significant biomarkers with markers of severity and clinical outcomes and studied IL-8 as an additional biomarker given its important predictive value in prior studies. In this restricted cohort, IL-6 was significantly associated with oxygenation index ( P = 0.02). Both IL-6 and IL-8 were associated with decreased VFDs and increased 28-day mortality. Future studies should be focused on examining larger numbers of patients with less severe ALI to further test the relative predictive value of plasma and mini-BAL biomarkers for clinically relevant outcomes, including VFDs and mortality, and for their prospective utility in risk stratification for future clinical trials.

Sign in / Sign up

Export Citation Format

Share Document